JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2024, 73(2):e15-e20 | DOI: 10.36290/csf.2024.020

Pharmaceutical care of patients with metabolic syndrome in Slovakia - questionnaire

Zuzana Mačeková1, Michaela Krivošová2, Ján Klimas3
1 Katedra lekárenstva a sociálnej farmácie, Univerzita veterinárskeho lekárstva a farmácie v Košiciach
2 Martinské centrum pre biomedicínu, Jesseniova lekárska fakulta v Martine, Univerzita Komenského Bratislava
3 Katedra farmakológie a toxikológie, Farmaceutická fakulta, Univerzita Komenského Bratislava

Introduction: Prevalence of both, metabolic syndrome (MetS) and cognitive impairment, is increasing with age. In general, MetS causes worsening of overall intellectual functioning and, also, a worsened overall health status. In elderly, cognitive impairment predicts increasing risk of drug-related problems, lower abilities of medication self-management and lower adherence. Early management of MetS and its components may also help to control cognitive decline and to identify high-risk individuals for potential mild cognitive impairment earlier.

Aim: To assess pharmacists' knowledge of MetS, to assess pharmacists' perceptions of the prevalence of cognitive impairment related to MetS, to determine their attitudes toward expanding pharmacy care for these patients, and to define barriers to expanding new services related to MetS screening in the public pharmacy setting. The study builds on our previous findings that MetS can accelerate a cognitive decline and therefore pharmaceutical care should be accordingly individualised.

Methods: We used on-line questionnaire.

Results and conclusion: The majority of participating pharmacists support the idea that patients with MetS need specific approach in pharmaceutical care (57%) and cognitive screening should be provided within pharmaceutical care (48%). Thus, there is a need for a rapid orientation tool that could help pharmacists estimate at-risk patients with potentially impaired cognitive performance.

Keywords: metabolic syndrome, cognitive impairment, elderly population, pharmaceutical care, questionnaire.

Accepted: June 12, 2024; Published: June 14, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mačeková Z, Krivošová M, Klimas J. Pharmaceutical care of patients with metabolic syndrome in Slovakia - questionnaire. Čes. slov. farm. 2024;73(2):e15-20. doi: 10.36290/csf.2024.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vaduganathan M, Mensah GA, Turco JV, et al.The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol. 2022;80 (25):2361-2371. Go to original source... Go to PubMed...
    2. World Heart Report 2023: Confronting the World's Number One Killer. Geneva, Switzerland. World Heart Federation. 2023.
    3. Mohamed SM, Shalaby MA, El-Shiekh RA. Metabolic syndrome: risk factors, diagnosis, pathogenesis, and management with natural approaches. Food Chem Adv. 2023;3: 1-14, 100335, ISSN 2772-753X. Go to original source...
    4. Harada CN, Natelson Love MC, Triebel K. Normal Cognitive Aging. Clin Geriatr Med, 2013;29 (4):737-752, doi:10.1016/j.cger.2013. 07. 002. Go to original source...
    5. Lee J, Kim HJ. Normal Aging Induces Changes in the Brain and Neurodegeneration Progress: Review of the Structural, Biochemical, Metabolic, Cellular, and Molecular Changes. Front Aging Neurosci. 2022;14, 931536. doi: 10.3389/fnagi.2022.931536 Go to original source... Go to PubMed...
    6. Pa J, Berry AS, Compagnone M, et al. Cholinergic enhancement of functional networks in older adults with MCI. Ann Neurol. 2013;73(6), doi:10.1002/ana.23874. Go to original source... Go to PubMed...
    7. Zimmerman B, Rypma B, Gratton G, Fabiani M. Age-related changes in cerebrovascular health and their effects on neural function and cognition: A comprehensive review. Psychophysiology. 2021;58 (7), doi:10.1111/psyp.13796. Go to original source... Go to PubMed...
    8. Assuncao N, Sudo FK, Drummond C, et al. Metabolic syndrome and cognitive decline in the elderly: A systematic review. PLoS One. 2018;13(3): e0194990, doi:10.1371/ journal.pone.0194990. Go to original source... Go to PubMed...
    9. Dobrowolski P, Prejbisz A, Kuryłowicz A. Metabolic syndrome - a new definition and management guidelines. A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons. Arch Med Sci. 2022;18(5):1133-1156. doi:10.5114/aoms/152921. Go to original source... Go to PubMed...
    10. Li D, Jia Y, Yu J, et al. Cognition impairment and risk of subclinical cardiovascular disease in older adults: The atherosclerosis risk in communities study. Front Aging in Neurosci. 2022;14:889543, doi: 10.3389/fnagi.2022.889543. Go to original source... Go to PubMed...
    11. Liu M, He Y, Jiang B, et al. Association between metabolic syndrome and mild cognitive impairment and its age difference in a Chinese community elderly population. Clin Endocrin. 2015;82(6):844-853, doi: 10.1111/cen.12734. Go to original source... Go to PubMed...
    12. Plácido AI, Herdeiro MT, Morgado M, et al. Drug-related Problems in Home-dwelling Older Adults: A Systematic Review. Clin Ther. 2020;42(4):559-572, ISSN 0149-2918. Go to original source... Go to PubMed...
    13. Rickles NM, Skelton JB, Davis J, Hopson J. Cognitive memory screening and referral program in community pharmacies in the United States. Int J Clin Pharm. 2013;36(2): 360-367. Go to original source... Go to PubMed...
    14. Climent MT, Pardo J, Muñoz-Almaraz FJ, et al. Decision Tree for Early Detection of Cognitive Impairment by Community Pharmacists. Front Pharmacol. 2018;9:1232, doi:10.3389/fphar.2018.01232. Go to original source... Go to PubMed...
    15. Macekova Z, Fazekas T, Stanko P, et al. Cognitive screening within advanced pharmaceutical care in elderly patients with suspected metabolic syndrome. Int. J. Gerontol. 2022;16:355-360.
    16. Macekova Z, Fazekas T, Krivosova M, et al. Identification of a Link between Suspected Metabolic Syndrome and Cognitive Impairment within Pharmaceutical Care in Adults over 75 Years of Age. Healthcare (Basel). 2023;1,11(5):718. doi: 10.3390/healthcare11050718. PMID: 36900723; PMCID: PMC10000537. Go to original source... Go to PubMed...
    17. Macekova Z, Krivosova M, Fazekas T, et al. Short cognitive screening in elderlies as a part of advanced pharmaceutical care in Slovak community pharmacies-The pilot study KOGIMET-SK. Eur Pharm J. 2022;69: 37-42, doi: 10.2478/afpuc-2022-0005. Go to original source...
    18. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23 (5):469-480. Go to original source... Go to PubMed...
    19. Zákon č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach a o zmene a doplnení niektorých zákonov.
    20. Winslade N, Taylor L, Shi S, et al. Monitoring Community Pharmacist's Quality of Care: A feasibility study of using pharmacy claims data to assess performance. BMC Health Serv Res. 2014;11(1). doi: 10.1186/1472-6963-11-12. Go to original source... Go to PubMed...
    21. Littlewood E, Ali S, Badenhorst J, et al. Community Pharmacies Mood Intervention Study (CHEMIST): feasibility and external pilot randomised controlled trial protocol. Pilot Feasibility Stud. 2019;5(71), doi:10.1186/s40814-019-0457-y. Go to original source... Go to PubMed...
    22. Fonseca AA, Lima TM, Castel-Branco M, Figueiredo IV. Feasibility of cardiovascular risk screening in Portuguese community pharmacies. Pharm pract. 2021;19 (2):2255. doi.org/10.18549/PharmPract.2021. 2. 2255. Go to original source... Go to PubMed...
    23. Štandardný postup pre výkon prevencie kardiovaskulárnych ochorení v podmienkach verejných lekární. ŠP 042, Vestník Ministerstva zdravotníctva SR, Osobitné vydanie, 15. 11. 2023, ročník.
    24. Hu M, Shu X, Yu G, et al. A Risk Prediction Model Based on Machine Learning for Cognitive Impairment Among Chinese Community-Dwelling Elderly People With Normal Cognition: Development and Validation Study. J Med Internet Res. 2021;23(2): e20298, doi.org/10.2196/20298. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.